Not to take away from the seriousness of your article and especially because I think most meds are bad for people, but

I'm in one of those moods.... :D

: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830056/

: "Statins and reversible cognitive impairment – evidence
: for
: Statins have been linked to short-term reversible cognitive
: impairment since early safety and tolerability testing
: [13]. During a phase I clinical trial of atorvastatin,
: escalating doses showed a dose-dependent adverse reaction
: of mild, transient, restlessness, euphoria, and mental

: confusion [13]. However, cognitive impairment was not
: reported significantly enough in the in phase II and III
: statin clinical trials to be recognized as a side effect
: [9–11]. Post-marketing surveillance can uncover side
: effects not identified in clinical trials and
: post-marketing surveillance of statins has revealed
: numerous case reports that characterize a transient and
: reversible cognitive loss. A review of 60 case reports
: described the main symptom of short-term memory loss that
: occurred a few months after the start of statin therapy or
: after an increase in dosage. Several case reports observed
: resolution of cognitive impairment upon discontinuation of
: the statin and recurrence of cognitive impairment upon
: rechallenging of the statin [14].

: A double blind placebo-controlled trial of lovastatin’s effect
: on cognitive functioning and mood showed detrimental
: effects on cognitive performance on four neuropsychological
: tests assessing attention, working memory, and overall
: mental efficiency [15]. A follow up double blind,
: randomized trial found a significantly worsened learning
: effect in participants taking statins compared to placebo
: [16]. The participants on statins were not able to learn
: from prior experiences as well as those on placebo. The
: strength of evidence is heightened by the randomization and
: controlled structure in these studies however, the strength
: of evidence is lowered by the small population of only 308
: participants.

: A patient survey-based analysis found evidence of cognitive
: impairment with variable onset and recovery courses, a
: clear relation to statin potency, and a significant
: negative impact on quality-of-life [17]. The Naranjo
: adverse drug reaction probability scale [18] was used to
: describe the relationship between statins and cognitive
: impairment. The Naranjo score is widely recognized as an
: accepted tool to measure the correlation between an adverse
: event and a medication increasing the strength of this
: evidence. Seventy-five percent of the cognitive adverse
: drug reports were determined to be probably or definitely
: related to statin therapy. In some patients, a diagnosis of
: dementia or Alzheimer’s disease was reportedly reversed
: upon discontinuation of the statin. Patients whose symptoms
: improved after discontinuation reproduced the symptoms
: after the statin was rechallenged. Some of those patients
: were rechallenged multiple times with continued recurrence
: of the adverse effect. Quality-of-life measures were
: significantly reduced in these patients, establishing the
: seriousness of this potentially avoidable adverse effect
: [17]."

:
: https://www.npr.org/2023/02/17/1157773608/the-presidents-personal-physician-has-issued-biden-a-clean-bill-of-health